Docetaxel represent the standard of care in patients with metastatic hormone sensitive prostate cancer (mHSPC). However, androgen receptor axis targeted (ARAT) therapies, also have shown to be effective. We aimed to analyze findings from RCTs investigating first-line treatment for mHSPC.

New Anti-Androgen Compounds Compared to Docetaxel in Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis

Marchioni, Michele;Di Nicola, Marta;Primiceri, Giulia;Castellan, Pietro;Schips, Luigi
2020

Abstract

Docetaxel represent the standard of care in patients with metastatic hormone sensitive prostate cancer (mHSPC). However, androgen receptor axis targeted (ARAT) therapies, also have shown to be effective. We aimed to analyze findings from RCTs investigating first-line treatment for mHSPC.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11564/711837
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 28
  • ???jsp.display-item.citation.isi??? ND
social impact